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Abstract
Background: Cancer of the cervix is the second commonest malignancy in females worldwide and
is the leading malignancy among women in Tanzania. Cancer of the cervix has been strongly
associated with Human Papilloma Virus (HPV) which is a sexually transmitted disease. However,
the role of HIV-1 in the aetiology of cancer of the cervix is less clear. Studies suggest that HPV and
HIV-1 infection are synergistic and therefore their dual occurrence may fuel increased incidence of
cancer of the cervix and AIDS. We therefore conducted a study to determine the association
between cancer of the cervix and HIV-1.
Methods: The study was carried out in Ocean Road Cancer Institute, Dar-es-salaam, Tanzania
between January and March 2007. A hospital-based case control design was used to study 138 cases
and 138 controls. The cases were consenting women 18 years and above with histologically
confirmed squamous cell carcinoma of the cervix, while the controls were consenting non-cancer
adult women attendants or visitors. The participants were counselled and tested for HIV-1 and
interviewed to assess risk factors for cancer of the cervix and HIV-1. Estimation of risk was done
by computing odds ratios and confidence intervals. Confounding and interaction between the
factors were assessed using logistic regression.
Results: HIV-1 prevalence was much higher among the cases (21.0%) than among the controls
(11.6%). In logistic regression, HIV-1 was associated with cancer of the cervix (OR = 2.9, 95% CI
= 1.4–5.9). Among the casesthe mean age was lower for HIV-1 infected (44.3 years) than HIV-1
uninfected women (54 years, p = 0.0001).
Conclusion:  HIV-1 infection is associated with invasive cancer of the cervix. Resource-
constrained countries with a high burden of HIV-1 and cervical cancer should adopt a high-risk
approach that targets HIV-1 positive women for screening of cervical cancer initially by utilizing
HIV/AIDS resources.
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Background
Cervical cancer is the most frequent cancer of women in
sub-Saharan Africa and the most common cause of can-
cer-related mortality [1]. The age-standardized incidence
of cervical cancer in sub-Saharan Africa is 30 to 67 per
100,000, which is two to ten times higher than that in
developed countries [1]. Unlike in developed countries
where the incidence of cervical cancer has declined, the
incidence of cervical cancer in sub-Saharan Africa has not
decreased but has even risen in some regions [1,2].
The majority of cervical cancer cases can be prevented by
screening and countries that have high coverage of cervi-
cal cancer screening have reduced invasive cervical cancer
incidence by about 70–90% [3]. Although about 40–90%
of women in developed countries are screened for cervical
cancer [4-6], less than5% of women in developing coun-
tries undergo cervical cancer screening [7,8]. In a situa-
tional analysis for cervical cancer diagnosis and treatment
in the East, Central and Southern African countries,
Chirenje and colleagues found that, though 95% of health
care facilities had the infrastructure for cervical screening,
very few women were screened due to lack of policy guide-
lines, infrequent supply of basic materials, and lack of
suitably qualified staff [7].
Cervical cancer is associated with many risk factors includ-
ing early sexual debut, having multiple sexual partners or
having sex with someone who has multiple sexual part-
ners, being HIV positive, a family history of cervical can-
cer, older women, smoking and poverty [7,9-11]. By far
the most important risk factor for cervical cancer is genital
infection with human papillomavirus (HPV) which is
responsible for virtually all cases [12,13]. There are many
types of HPV classified as low-risk types (LR) that are usu-
ally found in non-malignant lesions, and high-risk (HR)
types that are associated with cervical cancer [14,15]. HPV
16 and 18 are the most frequent types and cause about
70% of all cervical cancers worldwide. However, studies
from sub-Saharan Africa suggest that other HR-HPV types
are more prevalent and more diverse than elsewhere [16-
19]. The reasons for the unusual pattern of HPV in sub-
Saharan Africa are unclear but may be linked to HIV
[20,21].
Since 1993, the US Centres for Disease Control and Pre-
vention has included cervical cancer as one of the AIDS-
defining illnesses [22]. Several studies conducted in devel-
oped countries have demonstrated an increased risk of
invasive cervical cancer among HIV positive women
[23,24]. In sub-Saharan Africa, the situation is less clear
with conflicting results on the association between HIV
and invasive cervical cancer [17,25-34]. In part, this con-
fusion may explain the current situation in many coun-
tries in sub-Saharan Africa whereby the prevention and
control of cervical cancer is not linked to that of HIV. Tan-
zania, a low-resourced country in East Africa, with a heavy
burden of cervical cancer and a prevalence of HIV of 8%,
is no exception. The aim of the study was therefore to link
the twin burdens of cervical cancer and HIV by establish-
ing an association between invasive cancer of the cervix
and HIV-1 in Tanzania.
Methods
The study was carried out at Ocean Road Cancer Institute
(ORCI) in Dar-es-salaam, Tanzania between January and
March 2007. ORCI was established in 1996 and is the
only specialized centre for cancer treatment handling
both referral and self referral cancer patients from all over
Tanzania. It offers screening and treatment for cervical
cancer and HIV as well as palliative care. ORCI has four
wards with a total of 122 beds; two wards are for female
patients, one for male and another ward for children.
About 2500 new cancer cases are seen every year, two
thirds of whom are women. Cervical cancer cases com-
prise 60–65% of new female cancer cases. ORCI was cho-
sen because it is the only centre in Tanzania which
provides specialized treatment for cancer including chem-
otherapy, radiotherapy and also has cancer specialists.
The study was a hospital-based case-control design. The
cases were women aged 18 years or more, with newly
diagnosed histologically confirmed cancer of the cervix,
who attended ORCI between January and March 2007
and consented to participate in the study as well as to HIV
testing. They were recruited from the out and in-patient
departments and enrolled consecutively. The controls
were women aged 18 years or more, without cancer, who
attended ORCI between January and March 2007, and
consented to participate in the study as well as to HIV test-
ing. The controls were selected randomly from women
who had accompanied or come to visit patients or women
attendants of sick children within one week of selecting
the cases. We selected these women rather than other
patients in ORCI as controls because we wanted the con-
trols to be as close as possible to "community controls".
Patients who were too sick or unable to communicate in
the language of the interviewer were excluded from the
study.
Cervical cancer was confirmed on the basis of histological
results of cervical specimens. Three cervical specimens
from all new suspected cervical cancer patients were taken
and put in a 5 ml bottle containing formalin. The speci-
mens were then sent to Histology Department for exami-
nation. The pathologist issued a report confirming the
histological diagnosis of cervical cancer. Among the con-
trols, 80% agreed to undergo screening for cervical cancer
and were found to be negative for invasive cancer of theBMC Public Health 2008, 8:262 http://www.biomedcentral.com/1471-2458/8/262
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cervix. No details of pre-invasive disease among the con-
trols were available.
HIV serology was performed on cases and controls with
two consecutive capillus tests confirmed with commercial
ELISA (anti- HIV-1 micro Behringwerke, Marbug, Ger-
many) after HIV counselling. The principal investigator
with the help of two trained research assistants used a pre-
tested structured questionnaire to collect data on social
demographic characteristics (age, marital status, parity,
education level, occupation, region of residence, zone of
residence), reproductive factors (parity of woman, age at
first pregnancy, age at first coitus, use of oral contracep-
tives) and smoking. The questionnaire was translated into
Swahili in a standard procedure of translation and back-
translation.
Data was entered into EPIINFO version 6.04 and then
exported to SPSS version 13 for analysis. Continuous var-
iables were summarized into means and standard devia-
tion. Categorical variables were summarized into
frequencies and percentages. The Chi-square test was used
to compare categorical variables while the student's t test
was used for continuous variables. Association between
HIV and cancer of the cervix was established using Chi
square tests and Fisher's exact test. Odds ratios were used
to measure the strength of the association. All factors that
were statistically significant at a p value of 0.2 or less at
bivariate analysis were considered for multivariate analy-
sis.
Multivariate logistic regression was used to assess for
interaction and confounding. Product terms were formed
between the main predictor variable (HIV-1 infection, cat-
egorized into HIV+ and HIV-) and other variables (age,
parity, education, occupation, cigarette smoking and reli-
gion). We used the chunk test to see if there was interac-
tion by comparing the -2LL (negative two log likelihood)
of the reduced model (no interaction terms) and the full
model (with interaction terms). We found no significant
difference between these two models and concluded that
there was no interaction. All variables were tested for con-
founding since they were not effect modifiers. We noted
the odds ratio for HIV-1 when each of the variables was
left out of the model and also when it was put back in the
model. The variables that changed the odds ratio of HIV-
1 by more than 10% were considered confounders. The
variables were tested singly and also as groups of con-
founders. All statistical tests were two-sided.
Permission to carry out the study was obtained from Mak-
erere Clinical Epidemiology Unit, Faculty of Medicine
Research and Ethics Committee, Makerere University
School of Graduate Studies, Ocean Road Cancer Institute
Ethics Committee, and the National Institute of Medical
Research (NIMR) Tanzania. Written informed consent to
participate in the study and consent for HIV testing were
obtained from the participants. Participants who were
found to be HIV-1 positive were assisted to attend HIV
clinics as per national guidelines.
Results
A total of 145 cases and 152 controls were enrolled in the
study. Seven cases and 14 controls were excluded because
of refusal to test for HIV or language barrier. Thus 138
cases and 138 controls were available for final analysis.
Overall, 18 (6.5%) of the participants were from southern
zone, 27 (9.8%) were from central zone, 30 (10.9%) were
from southern highland, 42 (15.2%) from lake zone, 111
(40.2%) from eastern zone and 48 (17.4%) were from
northern zone. The mean age (SD) of the study partici-
pants was 50.0 (12.3) years and was significantly higher
among the cases compared to the controls (51.9 yrs vs.
47.4 yrs; p-value = 0.002). The proportion of cases com-
pared to controls decreased with increasing education
level (Chi square for trend = 12.654, p < 0.001). There was
no significant difference between cases and controls with
respect to occupation, residence, marital status and reli-
gion (Table 1).
The mean parity of the cases (6.0, SD = 2.7) was higher
than that of the controls (5.3, SD = 4.1) (Table 2). Women
with cervical cancer were more likely to have ever smoked
compared to the controls (OR = 5.3, 95% CI: 1.4–24.7).
Other risk factors such as sexually transmitted infections
(STIs), age at first coitus and use of oral contraceptives
were not statistically associated with cancer of the cervix.
Among the cases, 21.0% (29/138) were HIV-1 positive
compared to 11.6% (16/138) of the controls. At bivariate
analysis, HIV-1 positive status was associated with cervical
cancer among the women (OR = 2.0, 95% CI: 1.1–3.9). At
multivariate analysis, HIV-1 positive status was independ-
ently associated with cervical cancer (OR = 2.9, 95% CI:
1.4–5.9). Age and parity confounded the association
between HIV-1 and cervical cancer, raising the odds ratio
from 2.0 to 2.9. This effect was evident when age and par-
ity were treated as either continuous or categorical varia-
bles. However, both age (OR = 1.02, 95% CI 1.00 – 1.05
per year) and parity (OR = 1.14, 95% CI 1.02–1.28 per
birth) remained significantly associated with cervical can-
cer. Although education level was a confounder of the
relationship between HIV-1 and cervical cancer when
handled singly, raising the odds ratio from 2.0 to 2.3, it
was not necessary to control for it once parity and age
were controlled for. Smoking was significantly associated
with cervical cancer (OR = 5.7, 95% CI: 1.1 – 28.9) but
was not a confounder of the association between HIV-1
and cervical cancer (Table 3).BMC Public Health 2008, 8:262 http://www.biomedcentral.com/1471-2458/8/262
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Discussion
Our study showed that women with cervical cancer were
three times more likely to be infected with HIV-1 than
women without cervical cancer. Furthermore, the risk of
cervical cancer increased with age, higher parity, and
among those who had ever smoked. Our estimate for the
association between HIV-1 and cervical cancer of OR = 2.9
is consistent with the risk or odds ratio range of 1.6 to 2.4
reported in previous studies. Few studies have established
an association between HIV and invasive cancer of the cer-
vix in sub-Saharan Africa [1,26,27,33,34]. To explain this
situation, there are a number of plausible reasons.
First, though cancer of the cervix is the commonest malig-
nancy in women in sub-Saharan Africa, it is rare when
compared to many other diseases. Furthermore, invasive
cancer of the cervix is less frequent than pre invasive cervi-
cal cancer. Second, it has been suggested that the combi-
nation of cancer of the cervix and HIV is usually lethal and
many women with these two diseases die before they seek
health care [35,36]. However, the evidence for this view is
lacking, perhaps because of the difficulty of identifying
such cases. In contrast, Wabinga and colleagues in an
analysis of population based data linked to the cancer reg-
istry in Uganda showed that HIV did not influence sur-
vival of patients with invasive cervical cancer [37].
Third, methodological problems related to studies on
invasive cervical cancer may have contributed to the situ-
ation. A review of the literature suggests that studies that
have established an association between HIV and cancer
of the cervix, in general, share certain characteristics. The
common characteristics include the use of a population
rather than a hospital setting [27,29]; use of the cohort or
Table 1: Comparison of social demographic characteristics of 138 women with cancer of the cervix (cases) and 138 controls at Ocean 
Road Cancer Institute, Dar-es-Salaam, Tanzania
Variable Cases (138) 
n (%)
Controls (138) 
n (%)
p-value
Age in mean years (SD) 51.9 (12.3) 47.4 (11.9) 0.002
Education*
None 83(60.1) 55(39.9)
Primary 50(36.2) 67(48.6) <0.001
Secondary 3(2.2) 12(8.7)
Higher learning 2(1.4) 4(2.9)
Occupation
Housewife 21(15.2) 28(20.3)
Business 16(11.6) 24(17.4)
Peasant farmer 92(66.7) 62(44.9) 0.06
Salaried employee 3(2.2) 13(9.4)
Other 6(4.3) 11(8.0)
Residence
South 11(7.9) 7(5.1)
Southern highland 20(14.4) 10(7.2)
Eastern 49(35.5) 62(44.9) 0.13
Central 17(12.3) 10(7.2)
Lake zone 18(13.0) 24(17.4)
Northern 23(16.7) 25(18.1)
Religion
Catholic 36(26.1) 25(18.1)
Protestant 30(21.7) 43(31.5)
Born again 5(3.6) 6(4.3) 0.11
Muslim 48(34.8) 54(39.0)
Other 19(13.8) 10(7.2)
Marital status
Single 2(1.4) 4(2.9)
Married 94(68.1) 105(76.1) 0.62
Separated 12(8.7) 10(7.2)
Widowed 30(21.7) 19(13.8)
* Chi square for trend = 12.654BMC Public Health 2008, 8:262 http://www.biomedcentral.com/1471-2458/8/262
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cross sectional study design as opposed to the case control
design [26,27,29]; having large samples (usually thou-
sands of participants) [26,27,29,33,38]; and the use of
population controls [27,29]. It would therefore appear
that methodological issues including the challenges of
ensuring adequate power of studies (particularly since the
association between HIV and cancer of the cervix is
reported to be weak to modest), of minimizing bias, and
of controlling for confounding may have contributed to
the scarcity and negative findings of studies on invasive
cervical cancer and HIV.
Confounding, in particular, is of special interest given the
role of HPV in the aetiology of invasive cervical cancer. It
has been established that HPV is the cause of invasive cer-
vical cancer and it is believed that HPV negative cases of
invasive cervical cancer should not exist if high quality
methods for HPV detection are used [12,13,39]. There-
fore, in a study to assess the association between HIV and
invasive cervical cancer, it would be impossible to control
for HPV because there would be no HPV negative cases with
invasive cervical cancer. The implications of this are that
HPV cannot be assessed as a confounder of the association
between HIV and invasive cervical cancer. Instead, HIV
should be assessed as a confounder for the relationship
between HPV and invasive cervical cancer. However, even
this approach appears to be futile because one of the pre-
requisites for such an assessment would be to establish an
association between HIV and invasive cervical cancer
among the HPV negative cases of invasive cervical cancer who
theoretically do not exist.
Data on control for HPV among studies that have looked
at HIV and invasive cervical cancer is very limited and also
conflicting. Ter Meulen [31] and Moodley [28] controlled
for HPV and found no association between HIV and cer-
vical cancer. However, Hawes and colleagues found an
association between HIV and cervical cancer after control-
ling for HPV [26]. Although all the studies were hospital
based, the study by Hawes and colleagues was cross sec-
tional (perhaps providing the same source population for
cases and controls) and in addition had a much larger
sample size.
In our study, we did not measure HPV and therefore we
did not control for it in the analysis. It is possible that if
we had measured it with currently available methods for
detection of HPV and then adjusted for it, our estimate
may have been weakened or even been nullified. This
could perhaps be one of the reasons why Ter Meulen and
Moodley were not able to demonstrate an association
between HIV-1 and cervical cancer. Whether HPV should
be adjusted for in the association between HIV-1 and cer-
vical cancer or its precursors is an important epidemiolog-
ical issue that requires further study. Our estimate was
confounded by age and parity although the effect appears
to be small. Although education was a confounder, it was
not necessary to control for it because age and parity
formed a minimum confounder group. Previous studies
have reported that age and parity are independent risk fac-
Table 2: Comparison of risk factors for cancer of the cervix among 138 cases and 138 controls at Ocean Road Cancer Institute, Dar-es-
Salaam, Tanzania
Variable Cases (138) 
n (%)
Controls (138) 
n (%)
OR (95% CI)
Age in mean years (SD) 51.9 (12.3) 47.4 (11.9) 1.0 (1.0 – 1.1)
Parity in mean births (SD) 6.0 (2.7) 5.3 (4.1) 1.1 (1.0 – 1.2)
Age at first sexual coitus in mean years (SD) 17.7 (4.0) 17.4 (2.1) 1.0 (0.9 – 1.1)
HIV positive
No 109(79.0) 122(88.4) 1.0
Yes 29(21.0) 16(11.6) 2.0 (1.1 – 3.9)
Sexually Transmitted Infection
No 108(79.3) 109(79.0) 1.0
Yes 30(21.7) 29(21.0) 1.0 (0.6 – 1.9)
Oral Contraceptives
No 107(77.5) 111(80.4) 1.0
Yes 31(21.7) 27(19.6) 1.1 (0.6 – 2.0)
Ever smoked?
No 128(92.8) 136(98.6) 1.0
Yes 10(7.2) 2(1.5) 5.3 (1.4 – 24.7)
Table 3: Multivariate analysis of risk factors for cancer of the 
cervix among 138 cases and 138 controls at Ocean Road Cancer 
Institute, Dar-es-Salaam, Tanzania
Variable OR (95% CI)
HIV positive 2.9 (1.4 – 5.9)
Age (per year) 1.02 (1.00 – 1.05)
Parity (per birth) 1.14 (1.02 – 1.28)
Ever smoked? 5.7 (1.1 – 28.9)BMC Public Health 2008, 8:262 http://www.biomedcentral.com/1471-2458/8/262
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tors for cervical cancer and are also associated with HIV-1
infection [9,10]. Consistent with previous studies, smok-
ing was significantly associated with cervical cancer but
was not a confounder because it was not associated with
HIV-1 infection.
Although the mechanism by which HIV increases risk of
cervical cancer is not completely understood, studies sug-
gest that HIV-induced immunosuppression leads to an
inability to control the expression of HPV and the produc-
tion of HPV oncoproteins E6 and E7 [40,41]. According to
Hawes and colleagues, this risk appears to be associated
with increased HPV persistence that may result from
immunosuppression related to HIV. Furthermore the risk
is greater in women with CD4 counts less than 200 cells
per microliter and in those with high plasma HIV RNA
levels [19]. Studies have shown that HIV-1 infection is
associated with an increased rate of HPV infection, mainly
restricted to HR-HPV types which are the cause of invasive
cancer of the cervix [16,18,26].
Women with higher parity were more likely to have cervi-
cal cancer than women of lower parity, with the risk of cer-
vical cancer increasing by 1.1 times for each additional
birth. The findings of our study confirm previous work
that high-parity women are at high risk for cervical cancer
[9,10]. It has been suggested that parity is a marker of the
oestrogen-hormonal environment throughout the fertile
years of women as well as a marker of repeated cervical
trauma among highly parous women. It is not known
whether hormones intervene in cervical carcinogenesis
but oestradiol has been reported to induce immortaliza-
tion of HPV infected cells [42].
Consistent with previous findings [11], our study showed
that women who reported that they had ever smoked were
six times more likely to have cervical cancer than women
who had no history of smoking. Studies suggest that can-
cer causing chemicals (benzopyrene) from cigarette
smoke damage the cervix and make it vulnerable to HPV
infection. Women who smoke and also have HR-HPV
genital infection are twice as likely to have pre-cancerous
cells or to get cervical cancer.
Our findings have important implications for women
with HIV or cervical cancer in Tanzania and other sub-
Saharan countries which have high burdens of HIV and
cervical cancer. According to Chirenje and colleagues,
95% of health care facilities in East, Central and Southern
Africa have the infrastructure for cervical screening but the
major bottlenecks to screening and treatment of cervical
cancer are lack of policy guidelines, infrequent supply of
basic materials, and lack of suitably qualified staff [7].
Ngwalle and colleagues have rightly pointed out the
urgent need to develop a national policy and to introduce
systematic screening for cervical cancer in Tanzania [43].
Such a task, important and urgent as it is, is no easy under-
taking for a resource-constrained country like Tanzania.
However, the findings of our study suggest that a feasible
alternative for Tanzania could be adoption of a high-risk
approach that targets HIV positive women for cervical
cancer screening. The resources for the cervical screening
would initially come from the HIV/AIDS programmes. As
has been pointed out, antiretroviral therapy (ART) for HIV
provides a golden opportunity to improve cervical screen-
ing through the sharing of the ART resources and the fre-
quent check-ups of women on ART that can also be used
to screen for cervical cancer [44,45]. This approach would
enable the Tanzania Ministry of Health and Social Welfare
to develop the capacity for cervical screening and treat-
ment in a gradual and feasible manner, while mobilizing
additional resources and the population that would be
essential for a national cervical cancer screening and treat-
ment programme.
Our study had a number of potential limitations that may
have distorted our estimates. Selection bias among the
cases may have occurred in our study. The cases were
selected from the only cancer treatment centre in Tanzania
and thus were more likely to be representative, with regard
to the exposure (HIV infection), of cervical cancers in the
population than if they were selected from hospitals.
However, a very small proportion of all cases of cervical
cancer are seen in hospitals, and even fewer are referred to
ORCI. The cases seen in ORCI are likely to be those who
have access to health services (geographical, economic);
women with advanced cancer; and possibly the survivors
of HIV and cervical cancer.
In our study, the controls were mostly attendants or visi-
tors of the cases. Attendants are usually female relatives
who provide care for the patient while in hospital. The
attendants or visitors usually came from the same com-
munity as the cases. Thus the controls in our study were
"community" controls, derived from the same source
population as the cases, and therefore representative of
the non cervical cancer cases with regard to the exposure
(HIV infection). To validate this, we found that the fre-
quency of HIV-1 in the controls was similar to that in the
general population. However selection bias may have
occurred since the controls were significantly different
from the cases in age, parity and education. Selection bias
among the cases and controls could have caused an
under-estimate of our findings.
Measurement bias may have occurred among the 20% of
the controls who were not screened for cervical cancer
leading to under-estimation. Similarly, women with pre-
invasive disease could also have been included among theBMC Public Health 2008, 8:262 http://www.biomedcentral.com/1471-2458/8/262
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controls and caused under-estimation. Recall bias with
possible differential misclassification and over or under-
estimation of effect could have occurred in the assessment
of age of first sexual coitus. Since there was no blinding,
interviewer bias could also have occurred in the assess-
ment of risk factors. However, we took precautions by
training the interviewers and standardizing the instru-
ments. We did not measure HPV and therefore did not
control for it although as discussed earlier this could have
been problematic.
Conclusion
Notwithstanding these limitations, our study has demon-
strated that HIV-1 infection is associated with invasive
cancer of the cervix. Resource-constrained countries with
a high burden of HIV and cervical cancer should adopt a
high-risk approach that targets HIV-1 positive women for
screening of cervical cancer initially by utilizing HIV/AIDS
resources.
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